|Bid||6.15 x 1200|
|Ask||7.10 x 900|
|Day's range||6.11 - 6.39|
|52-week range||1.99 - 41.00|
|Beta (5Y monthly)||1.43|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Good morning, everyone, and thank you for joining today to discuss our second quarter financial results and business update. This morning, TherapeuticsMD issued a press release announcing its second quarter 2022 financial results. The press release and accompanying presentation are available on the company's website TherapeuticsMD in the investors and media section.
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 29.28% and 23.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Thank you for joining us for TherapeuticsMD's first quarter 2020 financial results conference call. Good afternoon, everyone, and thank you for joining today to discuss our first quarter financial results and business update. This afternoon, TherapeuticsMD issued a press release announcing its first quarter 2022 financial results.